<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678403</url>
  </required_header>
  <id_info>
    <org_study_id>14 7386 08</org_study_id>
    <nct_id>NCT02678403</nct_id>
  </id_info>
  <brief_title>Effect of Transcutaneous Electrical Nerve Stimulation in Peripheral Artery Disease TENS-PAD Study / TENS-AOMI</brief_title>
  <acronym>TENS-PAD</acronym>
  <official_title>Efficacy of Transcutaneous Electrical Nerve Stimulation in the Improvement of Walking Distance in Patients With Peripheral Artery Disease With Intermittent Claudication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: The investigators team recently carried out a proof of concept study testing the
      efficacy of one single 45-minute session of 10 Hz TENS prior to walking, versus placebo. In
      this randomized study, the investigators found that TENS significantly delayed pain onset and
      increased the pain-free walking distance in patients with class II PAD. From these
      encouraging results, the investigators now seek to assess the efficacy of an intervention
      that includes the daily use of TENS for 3 weeks (5 days a week) on walking distance in PAD
      (Leriche-Fontaine stage II). Methods/Design: prospective multicentre study / randomized
      controlled trial / double blinding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interventions (2 groups): Experimental group (TENS group): the treatment will consist of
      stimulation of the leg (frequency of 10 Hz, Biphasic, with a pulse width of 200 µs, maximal
      intensity below motor threshold), 45 minutes per day, in the morning before the exercise
      rehabilitation programme, for 3 weeks, 5 days per week. Control group (group SHAM): the
      stimulation placebo will be delivered according to the same modalities as for the TENS group
      but with a voltage level that vanishes automatically after 10 seconds of stimulation.

      15 days of interventions (TENS or SHAM) between J0 and J23, End of study for patient at
      J24-J25, two days for the last analyses who are the same of inclusion's visit J0.

      Primary outcome: walking distance (metres) measured on a treadmill with a standardized
      protocol. Secondary outcomes: transcutaneous oxygen pressure (TcPO2) measured during a
      Strandness exercise test, peak oxygen uptake (VO2 peak) (ml.min.kg-1), endothelial function
      (EndoPAT®), ankle-brachial pressure index, body mass index, lipid profile (LDL-C, HDL-C,
      Triglycerides), fasting glycaemia, HbA1c, WELCH questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>walking distance without pain (in meters)</measure>
    <time_frame>Change between J0 and J25 (15 days)</time_frame>
    <description>the evolution of the claudication distance between the start and the end of the study (1 session of TENS each day , 15 days in total) in the two intervention group (TENS vs SHAM). Measure of change between inclusion and end of study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximal oxygen consumption (VO2peak in ml.min)</measure>
    <time_frame>Change between J0 and J25 (15 days)</time_frame>
    <description>maximal oxygen consumption (VO2peak in ml.min) Measure of change between inclusion and end of study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>1 - TENS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment will consist of Transcutaneous electrical nerve stimulation (TENS): stimulation of the leg (frequency of 10 Hz, Biphasic, with a pulse width of 200 µs, maximal intensity below motor threshold), 45 minutes per day, in the morning before the exercise rehabilitation programme, for 3 weeks, 5 days per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - SHAM group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>SHAM Transcutaneous electrical nerve stimulation (TENS) : the stimulation placebo will be delivered according to the same modalities as for the TENS group but with a voltage level that vanishes automatically after 10 seconds of stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous electrical nerve stimulation (TENS)</intervention_name>
    <description>Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.</description>
    <arm_group_label>1 - TENS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SHAM Transcutaneous electrical nerve stimulation (TENS)</intervention_name>
    <description>Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.</description>
    <arm_group_label>2 - SHAM group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral Leriche stage II PAD, admitted to cardiovascular Rehabilitation Unit

          -  Men or women

          -  Able to take part in an out-patient rehabilitation programme

          -  Clinically stable

          -  Sedentary

          -  Provided informed consent to participate in the study

        Exclusion Criteria:

          -  Ward of court

          -  Walking disorders related to orthopaedic or neuromuscular disease

          -  Participation in a structured physical reconditioning programme in the month before
             the study

          -  Renal insufficiency requiring dialysis

          -  Known and documented myopathy

          -  Progressive cancer

          -  Associated progressive disease causing a deterioration in general health

          -  Participation in another research protocol

          -  Skin disorder making it impossible to use TENS

          -  Absolute contra-indication to physical activity

          -  Presence of pacemaker / defibrillator

          -  Pregnant women in the 1st trimester / 12 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc LABRUNEE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc LABRUNEE, MD</last_name>
    <phone>05 61 32 21 03</phone>
    <phone_ext>33</phone_ext>
    <email>labrunee.m@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent GREMEAUX, MD</last_name>
      <phone>03 80 29 38 15</phone>
      <phone_ext>+33</phone_ext>
      <email>vincent.gremeaux@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of La Réunion</name>
      <address>
        <city>Saint Pierre</city>
        <zip>97 448</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mélanie RIEDEL, MD</last_name>
      <phone>02 62 35 90 00</phone>
      <phone_ext>+33</phone_ext>
      <email>melanie.riedel@chu-reunion.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique de Saint-Orens</name>
      <address>
        <city>Saint-Orens de Gameville</city>
        <zip>31650</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc BOUSQUET, MD</last_name>
      <phone>05 61 39 33 33</phone>
      <phone_ext>+33</phone_ext>
      <email>marc.bousquet4@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toulouse University Hospital (CHU de Toulouse)</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc LABRUNEE, MD</last_name>
      <phone>05 61 32 21 03</phone>
      <phone_ext>+33</phone_ext>
      <email>labrunee.m@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Arnaud LENDRIEUX</last_name>
      <phone>5 61 77 83 50</phone>
      <phone_ext>+33</phone_ext>
      <email>lendrieux.a@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Marc LABRUNEE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>February 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral artery disease</keyword>
  <keyword>transcutaneous electrical nerve stimulation</keyword>
  <keyword>walking ability</keyword>
  <keyword>endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

